IP Library Granted Patent US 7,794,754
Granted Patent B2
US 7,794,754 · App. 11/385,513 · Granted Sep 14, 2010

Methods for fine powder formation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,794,754
App. No.
11/385,513
Granted
Sep 14, 2010
Kind
B2
Abstract

Improved methods for forming fine particles of a material have been developed, wherein the method steps include dissolving the material in a solvent to form a dilute solution, immobilizing the dilution solution, and then removing the solvent to yield particles of the material. Methods of immobilizing the dilute solution include freezing, gelation, and chelation. In a preferred embodiment, the immobilized solvent is removed by lyophilization, i.e. reducing the ambient pressure while avoiding application of sufficient heat to power a phase transition. Essentially any material and solvent for the material can be used in the methods described herein. Proteins and peptides in an aqueous solvent are the preferred systems.

Claims (8)

1. A method for making fine particles of a drug material comprising:

(a) dissolving a drug material in a solvent to form a solution,

(b) immobilizing the solution by freezing in a liquid nonsolvent, in a dry gas, in a vacuum, or in a reactor with controlled counter current gas stream; and

(c) removing the solvent from the solution by reducing the ambient pressure to a pressure sufficiently low to induce a phase transition in the solvent, thereby yielding particles comprising the drug material having a diameter between 0.5 μm and 10 microns.

2. The method of claim 1 , wherein the drug material comprises a therapeutic or a diagnostic agent.

3. The method of claim 2 , wherein the agent is a therapeutic agent selected from the group consisting of vasoactive agents, neuroactive agents, hormones, anticoagulants, immunomodulating agents, cytotoxic agents, antibiotics, antivirals, antisense nucleic acid sequences and fragments, antigens, and antibodies.

4. The method of claim 2 , wherein the agent is a therapeutic agent selected from the group consisting of insulin, calcitonin, heparin, felbamate, and hormones.

5. The method of claim 4 , wherein the therapeutic agent is insulin.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Apr 5, 2024
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: MANNKIND CORPORATION; MANNKIND LLC
Reel/Frame 067024/0082 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2019
From: DEERFIELD PRIVATE DESIGN FUND II, L.P.; DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P.; HORIZON SANTE FLML SARL
To: MANNKIND CORPORATION
Reel/Frame 050044/0138 →
SECURITY INTEREST Recorded Aug 13, 2019
From: MANNKIND CORPORATION; MANNKIND LLC
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 050044/0181 →
RELEASE OF SECURITY INTEREST Recorded Nov 10, 2016
From: AVENTISUB LLC
To: MANNKIND CORPORATION
Reel/Frame 040588/0008 →
PATENT SECURITY AGREEMENT Recorded Sep 26, 2014
From: MANNKIND CORPORATION
To: AVENTISUB LLC
Reel/Frame 033831/0110 →
SECURITY AGREEMENT Recorded Jul 3, 2013
From: MANNKIND CORPORATION
To: DEERFIELD PRIVATE DESIGN FUND II, L.P.; DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P.; HORIZON SANTE FLML SARL
Reel/Frame 030740/0123 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2008
From: FELDSTEIN, ROBERT; STEINER, SOLOMON S.
To: PHARMACEUTICAL DISCOVERY CORPORATION
Reel/Frame 020378/0873 →
CHANGE OF NAME Recorded Jan 17, 2008
From: PHARMACEUTICAL DISCOVERY CORPORATION
To: MANNKIND CORPORATION
Reel/Frame 020378/0929 →
CHANGE OF NAME Recorded Jul 26, 2007
From: PHARMACEUTICAL DISCOVERY CORPORATION
To: MANNKIND CORPORATION
Reel/Frame 019612/0070 →